SCHEMBL2963776

SCHEMBL2963776

Cc1ccc(C(=O)Nc2cccc(N(C)C)c2)cc1NC(=O)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 11/20 0.68
SMO Q99835 2/20 0.68
MAPT P10636 2/20 0.61
KDM4E B2RXH2 1/20 0.61
ALDH1A1 P00352 1/20 0.61
RAF1 P04049 1/20 0.61
TP53 P04637 1/20 0.61
CYP1A2 P05177 1/20 0.61
CYP3A4 P08684 1/20 0.61
CYP2C9 P11712 1/20 0.61
BRAF P15056 1/20 0.61
HPGD P15428 1/20 0.61
ALOX15 P16050 1/20 0.61
MAPK11 Q15759 1/20 0.61
HSD17B10 Q99714 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
HDAC6 Q9UBN7 1/20 0.61
NR1H4 Q96RI1 4/20 0.60
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6873810 0.86 MAPK14 (0.74) MAPK14SMOMAPTKDM4EALDH1A1
SCHEMBL2972993 0.86 MAPK14 (0.87) MAPK14SMOMAPTKDM4EALDH1A1
SCHEMBL2978300 0.83 MAPK14 (0.70) MAPK14SMOMAPTKDM4EALDH1A1
SCHEMBL2969610 0.83 MAPK14 (0.85) MAPK14SMOMAPTKDM4EALDH1A1
SCHEMBL2975508 0.81 MAPK14 (0.64) MAPK14SMOMAPTKDM4EALDH1A1
SCHEMBL2979735 0.81 MAPK14 (0.70) MAPK14SMOMAPTKDM4EALDH1A1
SCHEMBL2976969 0.81 MAPK14 (0.64) MAPK14SMOMAPTKDM4EALDH1A1
SCHEMBL6476701 0.81 MAPK14 (0.79) MAPK14SMOMAPTKDM4EALDH1A1
SCHEMBL6526624 0.80 MAPK14 (0.65) MAPK14SMOMAPTKDM4EALDH1A1
SCHEMBL2978663 0.80 MAPK14 (0.77) MAPK14SMOMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772432-B2 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA AB (SE) 2010-08-10 US disclosed
CN-1243724-C Amide derivatives which are useful as cell factor inhibitors ASTRA ZENECA LTD (SE) 2006-03-01 CN disclosed
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA 2005-02-17 US disclosed
US-6821965-B1 IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION ASTERZENECA AB (SE) 2004-11-23 US disclosed
CN-1330631-A Amide derivatives which are useful as cell factor inhibitors ASTRA ZENECA LTD (SE) 2002-01-09 CN disclosed
EP-1102743-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS AstraZeneca AB (SE) 2001-05-30 EP disclosed
WO-2000007980-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors IL6, IL6ST, IL2 MAPK14 1775/4885SMO 4706/4885MAPT 4659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.